HALTED

I TRIED MY 2 ONLINE ACCOUNTS, AND NOTHING, MY BROKER DID HIS.MAJIC, I DON'T LIKE USING THM, FEES TOO HIGH

I COVERED AT $25.00
I DIDN'T HAVE THE -ALLS TO STICK IT OUT.

I SHORTED @ $63.25 , BUT AFTER GETTING STUCK IN AND SEEING THE $120.00 HIGH, I ALMOST CRAPPED MYSELF.

DRYS HALTED AGAIN 1:52

HALTED AGAIN 11:13

HALTED AGAIN @ 10:43, NOT GOOD

JUST COVERED @ $25.00 , IT'S GREAT WHEN A PLAN COMES TOGETHER, BUT I WILL SAY, THAT $120.00 PRICE MADE ME ALMOST CRA P MY PANTS

SHORTED AT $63.25

Tuesday, 11/15/16 10:55:05 AM
Re: None
Post #
13131
of 13595 Go
THE BOTTOM WILL BE IN @ $25 - $30

LOL

After Hours
Time (ET)
Pre-market
Price
Pre-market
Share Volume
16:06 107.01 13
16:06 107.96 20
16:06 119.97 5

EXACTLY, THE LONGER ITS HALTED,THE LOWER IT'S GOING.

THIS WASN'T WORTH THE $4.65 AFTER THE SPLIT.

HALTED 11:52

THE BOTTOM WILL BE IN @ $25 - $30

NOT HALTED

JUST SHORTED @ $ 63.25

DOWNHILL FROM HERE

You guys had to have known this was going to happen

It was in the filings, This is what I was hoping for, You knew the dilution was coming and most ignored it.

This is the opening I was looking for, I picked up a bunch on the dive under .04 and hope to pick up more around the same price, Just surprised it didn't go lower. GL2A

Also, Volume VERY low for this amount of dilution

The saving grace for you guys may be they may have sold them on the run-up, funny how they all knew when to exercise these convertible notes,Hmmmmm

They added another 11m shares since sept, as of Oct 13 they have 29m, 're 8k, this is bad news for you guys, Good luck

It will be easy to prove

If they stay above $1.00 they will be able satisfy both requirements for continued listing 5550a and 5550b

the first one covers the $1.00 Min. for 10 days and the 2nd covers the ( either a minimum of $2.5 million in stockholders' equity or a market capitalization of at least $35 million. )

there are a little under 35m shares outstanding hence the capitalization of at least $35 million

BGMD IR, GOOD LUCK !!!!!

No Short-Selling or Hedging by Aspire Capital
Aspire Capital has agreed that neither it nor any of its agents, representatives and affiliates shall engage in any direct or indirect short-selling or hedging, which establishes a net short position with respect to our Common Stock during any time prior to the termination of the Purchase Agreement.

Whatttttttttttttttttttttt ????

The Min. Amount Of Time Is 90 Days

It was given to the FDA in Feb.

I think it may be close because the FDA Hasen't asked for more information, last submission, they had asked within 30 days for more info.

From 10K 2013 ( Fujirebio submitted its 510(k) to the FDA in July 2012 and received a letter from the FDA in July 2012 requesting additional information )


Ill repost this.


On average, it takes 5 months for the FDA to review and clear a medical device 510(k) application.

About 2/3 of all 510(k) submissions are cleared within 6 months

The FDA sets internal goals to review and respond to 510(k) submissions within 90 days. However, that’s a little misleading when taken at face value. When you submit a 510(k) submission to the FDA, the clock starts. However, when they come back to you with an Additional Information (AI)” request, they stop the clock. The FDA does not count the days when they are waiting on you to provide the additional information they need to determine Substantial Equivalence.

Therefore, many people think they have a good chance of getting their 510(k) cleared within 90 days but the reality is that only 28% of 510(k) submissions cleared in 2013 were done within 3 months. So, the 90 day goal set by the FDA should largely be ignored when you are trying to determine how long it will actually take to get your 510(k) reviewed and cleared.

http://www.emergogroup.com/research/fda-510k-review-times-research

You forgot about Abbott's Architect Galectin 3 Assay 510K submission that was submitted in Feb, News will be out very soon, that alone will drive this stock to an easy double if Cleared.

Heres the Aspire Purchase Agreement, Good Luck

http://www.sec.gov/Archives/edgar/data/1407038/000119312513022374/d472910d8k.htm

Summary of Terms of Purchase Agreement with Aspire Capital
Under the Purchase Agreement, the Company initially will issue 132,743 shares of its common stock to Aspire Capital in consideration for entering into the Purchase Agreement (the “Commitment Shares”). Under the Purchase Agreement, after the SEC declares the initial registration statement effective, on any business day on which the closing sale price of the Company’s common stock equals or exceeds $1.00 per share, over the 24-month term of the Purchase Agreement, the Company has the right, in its sole discretion, to present Aspire Capital with a purchase notice (each, a “Purchase Notice”) directing Aspire Capital to purchase up to 100,000 Purchase Shares per business day; however, no sale pursuant to such Purchase Notice may exceed $500,000 per business day. Furthermore, in connection with the public offering the Company commenced on January 24, 2013, the Company has agreed that it will not sell Purchase Shares to Aspire Capital under the Purchase Agreement for a period of six months following the date of the Purchase Agreement. The purchase price per Purchase Share pursuant to such Purchase Notice (the “Purchase Price”) is the lower of (i) the lowest sale price for the Company’s common stock on the date of sale or (ii) the arithmetic average of the three lowest closing sale prices for the Company’s common stock during the 12 consecutive business days ending on the business day immediately preceding the purchase date of those securities. The applicable Purchase Price will be determined prior to delivery of any Purchase Notice.


In addition, on any date on which the Company submits a Purchase Notice to Aspire Capital in the amount of 100,000 Purchase Shares, the Company also has the right, in its sole discretion, to present Aspire Capital with a volume-weighted average price purchase notice (each, a “VWAP Purchase Notice”) directing Aspire Capital to purchase an amount of the Company’s common stock equal to a percentage not to exceed 30% of the aggregate shares of common stock traded on the next business day (the “VWAP Purchase Date”), subject to a maximum number of shares determined by the Company (the “VWAP Purchase Share Volume Maximum”). The purchase price per Purchase Share pursuant to such VWAP Purchase Notice (the “VWAP Purchase Price”) shall be the lower of (i) the closing sale price on the date of sale and (ii) 95% of the volume weighted average price for the Company’s common stock traded on the NASDAQ Global Market on (i) the VWAP Purchase Date if the aggregate shares to be purchased on that date does not exceed the VWAP Purchase Share Volume Maximum, or (ii) the portion of such business day until such time as the aggregate shares to be purchased will equal the VWAP Purchase Share Volume Maximum. Further, if the sale price of the Company’s common stock falls on the VWAP Purchase Date below the greater of (i) 90% of the closing price of our common stock on the business day immediately preceding the VWAP Purchase Date or (ii) the price set by us in the VWAP Purchase Notice (the “VWAP Minimum Price Threshold”), the VWAP Purchase Price will be determined using the percentage in the VWAP Purchase Notice of the total shares traded for such portion of the VWAP Purchase Date prior to the time that the sale price of the Company’s common stock fell below the VWAP Minimum Price Threshold and the volume weighted average price of the common stock sold during such portion of the VWAP Purchase Date prior to the time that the sale price of the common stock fell below the VWAP Minimum Price Threshold.

Yes it is, they must be trading above $1.00 in.order to sell shares to ASpire. They were under $1.00 for a long time in 2013 and did not trigger a buy because of that, I think the company knew earnings would be not good in Q1 hence the stock offering and keeping ASpire on the Sidelines as a sure thing, it would be hard for them to raise cash if the 510k has problems, Smart move by the company IMHO GOOD LUCK

No they didn't, The deal is BGMD Must be above $1.00 before they can buy.

From the 10K filing, Somethings happening here In My Opinion

Company Has $9M from offering, $4.3M cash left at end of 1st Q balance sheet, plus $12M from Aspire that has to be used by May 2015, Thats $25.3M , They have a burn rate now of $2.2M, And they state that this will be sufficient to fund its operations and service its debt into the second quarter of 2015, Huh , How do they figure that !!!!!

There should be plenty left over, With the burn rate of $2.2M, Outstanding balance Due of $6.3 million under a secured term loan facility, Add another $1M a year because they are doubling their sales force to 10, If they pay off the GE Debt in full, Add all them up and you only get $19.1M , that leaves $6.2M left over, Somethings not adding up here, And in my opinion its a good sign, DOUBLING THEIR SALES FORCE ??? Do they already know something about the 510k filing that we dont know ????

From the C/C . Kevin DeGeeter - Ladenburg Thalmann
Hey, good morning guys. Thanks for the update. A few quick questions here. Can you just—one of them sort of housekeeping. You talk about doubling the U.S. field sales force. Can you put some numbers on that – where were we in 2Q ’13 and what’s the target for 2Q ’14?

Paul Sohmer - President, Chief Executive Officer
Yeah, we expect to be at approximately 10 field sales people in the field by the end of the quarter. Some



The Company believes that its existing cash, funding from the April 2014 public offering and availability of up to $12.0 million under its common stock purchase agreement with Aspire Capital Fund, LLC, or Aspire, (Note 6) pursuant to which approximately $6.8 million would be available to the Company at March 31, 2014, will be sufficient to fund its operations and service its debt into the second quarter of 2015. The Company has not yet sold any shares under its common stock purchase agreement with Aspire, which expires in May 2015.

On average, it takes 5 months for the FDA to review and clear a medical device 510(k) application.

About 2/3 of all 510(k) submissions are cleared within 6 months

The FDA sets internal goals to review and respond to 510(k) submissions within 90 days. However, that’s a little misleading when taken at face value. When you submit a 510(k) submission to the FDA, the clock starts. However, when they come back to you with an Additional Information (AI)” request, they stop the clock. The FDA does not count the days when they are waiting on you to provide the additional information they need to determine Substantial Equivalence.

Therefore, many people think they have a good chance of getting their 510(k) cleared within 90 days but the reality is that only 28% of 510(k) submissions cleared in 2013 were done within 3 months. So, the 90 day goal set by the FDA should largely be ignored when you are trying to determine how long it will actually take to get your 510(k) reviewed and cleared.

http://www.emergogroup.com/research/fda-510k-review-times-research

Last trade of the day was 967,800 Shares @$1.3569 At 16:02

Yup, 30,700 shares @1.50

There are currently 219,551,282 common shares outstanding


and the company is authorized to issue 1,000,000,000 common shares.



Best regards,

Tiffany Erickson

Transfer Agent Manager





Nevada Agency and Transfer Company
50 West Liberty Street, Suite 880
Reno NV 89501



Tel: 775-322-0626
Fax: 775-322-5623

Email: tiffany@natco.org



www.natco.org

THIS IS THE LAST SEC FILING

http://www.sec.gov/cgi-bin/browse-edgar?company=SafeCode+Drug+Technologies+Corp.&owner=exclude&action=getcompany

January 6, 2014
Via E-mail Mr. Itamar Zer Chief Financial Officer Safecode Drug Technologies Corp 6 Meever HaMiltah Street Jerusalem 97761, Israel
Re: Safecode Drug Technologies Corp Form 10-K for the Fiscal Year Ended December 31, 2012 Filed March 25, 2013 File No.: 000-54656
Dear Mr. Zer:
We issued comments to you on the above captioned filing on November 25, 2013. As of the date of this letter, these comments remain outstanding and unresolved. We expect you to provide a complete, substantive response to these comments by January 21, 2014.
If you do not respond, we will, consistent with our obligations under the federal securities laws, decide how we will seek to resolve material outstanding comments and complete our review of your filings and your disclosure. Among other things, we may decide to release publicly, through the agency’s EDGAR system, all correspondence, including this letter, relating to the review of your filing, consistent with the staff’s decision to release publicly comment letters and response letters relating to disclosure filings it has reviewed. You can find more information about the staff’s decision to release filing correspondence at http://www.sec.gov/divisions/corpfin/cfannouncements/edgarcorrespondence.htm, http://www.sec.gov/news/press/2004-89.htm and http://www.sec.gov/news/press/2005-72.htm.
You may contact Tara Harkins, Staff Accountant, at (202) 551-3639 or Lynn Dicker, Reviewing Accountant, at (202) 551-3616 if you have questions regarding these comments. In this regard, do not hesitate to contact me at (202) 551-3643.
Sincerely,
/s/ Kevin L. Vaughn for Amanda Ravitz Assistant Director

Whose Turn Is It To Paint The Tape

Because they went from OTCBB TO PINK SHEETS, from reporting co. To non reporting co. Simple as that

If The Company Just Comes Out And Says

HELLO

We would double in price from here, Its just to let us know you're still alive and well.

Spike, there's nothing we can do about that, just wait it out

You'll All Know When This Is About To PoP When

You get a whole lot of posters you've never seen before come here pumping SAFC with no news out, That will be the telltail sign.

WATCH FOR IT, IT'S COMING

There are currently 219,551,282 common shares outstanding


and the company is authorized to issue 1,000,000,000 common shares.



Best regards,

Tiffany Erickson

Transfer Agent Manager


IMHO, If the company were dead as some on here think, They would have DUMPed this stock ON THE MARKET and put the OS At 1B and the A/S AT 2B


Nevada Agency and Transfer Company
50 West Liberty Street, Suite 880
Reno NV 89501



Tel: 775-322-0626
Fax: 775-322-5623

Email: tiffany@natco.org



www.natco.org

Seems like that was it boyz, Better luck next year, LOL

Bid Now Up To 8M

Yeah, I've been in for a while and haven't

seen that size bids ever, makes you wonder if they're real or if the M/M is setting this up for a run